Products for Research Use Only

Maraviroc-d6

CAT: 0804-HY-13004SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13004SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV[1][2].
CAS Number
1033699-22-7
UNSPSC
12352005
Target
CCR; HIV; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; GPCR/G Protein; Immunology/Inflammation; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Inflammation/Immunology; Cancer; Endocrinology
Solubility
10 mM in DMSO
Smiles
C(C[C@H](NC(=O)C1CCC(F)(F)CC1)C2=CC=CC=C2)N3[C@@H]4C[C@@H](C[C@H]3CC4)N5C(C(C([2H])([2H])[2H])C([2H])([2H])[2H])=NN=C5C
Molecular Formula
C29H35D6F2N5O
Molecular Weight
519.70
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005 Nov;49 (11) :472|[3]Mencarelli A, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep. 2016 Aug 5;6:30802.|[4]Romero-Sánchez MC, et al. Effect of maraviroc on HIV-disease progression-related biomarkers. Antimicrob Agents Chemother. 2012 Nov;56 (11) :5858-64.|[5]Huilin Mou, et al. NRSF and CCR5 Established Neuron-glia Communication during Acute and Chronic Stresses. Journal of Drug Metabolism & Toxicology. January 10, 2016.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products